What is TransCode Therapeutics?
TransCode Therapeutics is a biotechnology research and development firm established in 2016 and headquartered in Boston, Massachusetts. The company is dedicated to discovering and developing innovative diagnostics and therapeutics for cancer detection and treatment, with a strategic focus on addressing metastasis. Leveraging its pipeline of RNAi-based technologies, TransCode Therapeutics aims to advance data-driven cancer diagnostics and targeted treatment solutions for the healthcare and medical research sectors.
How much funding has TransCode Therapeutics raised?
TransCode Therapeutics has raised a total of $35M across 2 funding rounds:
Share Placement
$10M
Debt
$25M
Share Placement (2025): $10M, investors not publicly disclosed
Debt (2025): $25M led by CK Life Sciences Int'l
Key Investors in TransCode Therapeutics
CK Life Sciences Int'l
CK Life Sciences International (Holdings) Inc. specializes in the research, development, and commercialization of innovative biotechnology products and services. The company focuses on providing solutions in the fields of healthcare, agriculture, and environmental protection. Their intended clients include pharmaceutical companies, agricultural businesses, and environmental organizations seeking advanced biotechnological applications. CK Life Sciences aims to enhance the quality of life through sustainable and effective biotechnological solutions.
What's next for TransCode Therapeutics?
The recent major enterprise-level funding signifies a pivotal moment for TransCode Therapeutics, likely enabling accelerated development of its oncology pipeline and expansion into new therapeutic areas. This strategic backing is expected to fuel further research and clinical trials, positioning the company for significant growth and market impact in the competitive biotechnology landscape.
See full TransCode Therapeutics company page
